


## ST 1535

Cat. No.:	HY-105003
CAS No.:	496955-42-1
Molecular Formula:	C <sub>12</sub> H <sub>16</sub> N <sub>8</sub>
Molecular Weight:	272.31
Target:	Adenosine Receptor
Pathway:	GPCR/G Protein
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	ST 1535 is a potent and orally active A2A adenosine receptor antagonist. ST 1535 shows antiparkinsonian activity and antitremorigenic effects. ST 1535 has the potential for the research of Parkinson's disease <sup>[1][2]</sup> .																
<b>IC<sub>50</sub> &amp; Target</b>	A2a adenosine receptor																
<b>In Vitro</b>	ST 1535 (0-1000 nM) inhibits <a href="#">forskolin</a> (HY-15371)-induced cAMP formation in CHO cells with IC <sub>50</sub> s of 510, 353, 950, >1000 nM for hA1, hA2A, hA2B, hA3, respectively <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.																
<b>In Vivo</b>	<p>ST 1535 (0, 5, 10 mg/kg; p.o.) antagonizes catalepsy induced by i.c.v. administration with the A2A adenosine agonist <a href="#">CGS 21680</a> (HY-13201)<sup>[1]</sup>.</p> <p>ST 1535 (10, 20, 40 mg/kg; i.p.) increases the number of contralateral turns induced by <a href="#">L-DOPA</a> (HY-N0304) in rats<sup>[2]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>5-6 weeks CD1 male mice<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>0, 5, 10 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>P.o.</td> </tr> <tr> <td>Result:</td> <td>Antagonized catalepsy induced by i.c.v. administration with the A2A adenosine agonist CGS 21680.</td> </tr> </table> <table border="1"> <tr> <td>Animal Model:</td> <td>Male Sprague Dawley rats<sup>[2]</sup></td> </tr> <tr> <td>Dosage:</td> <td>10, 20, 40 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>I.p.</td> </tr> <tr> <td>Result:</td> <td>Significantly increased the number of contralateral turns induced by L-DOPA (3 mg/kg i.p.) at 20 and 40 mg/kg.</td> </tr> </table>	Animal Model:	5-6 weeks CD1 male mice <sup>[1]</sup>	Dosage:	0, 5, 10 mg/kg	Administration:	P.o.	Result:	Antagonized catalepsy induced by i.c.v. administration with the A2A adenosine agonist CGS 21680.	Animal Model:	Male Sprague Dawley rats <sup>[2]</sup>	Dosage:	10, 20, 40 mg/kg	Administration:	I.p.	Result:	Significantly increased the number of contralateral turns induced by L-DOPA (3 mg/kg i.p.) at 20 and 40 mg/kg.
Animal Model:	5-6 weeks CD1 male mice <sup>[1]</sup>																
Dosage:	0, 5, 10 mg/kg																
Administration:	P.o.																
Result:	Antagonized catalepsy induced by i.c.v. administration with the A2A adenosine agonist CGS 21680.																
Animal Model:	Male Sprague Dawley rats <sup>[2]</sup>																
Dosage:	10, 20, 40 mg/kg																
Administration:	I.p.																
Result:	Significantly increased the number of contralateral turns induced by L-DOPA (3 mg/kg i.p.) at 20 and 40 mg/kg.																

---

## REFERENCES

---

- [1]. Stasi MA, et al. ST 1535: a preferential A2A adenosine receptor antagonist. *Int J Neuropsychopharmacol.* 2006 Oct;9(5):575-84.
- [2]. Tronci E, et al. Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats. *Eur J Pharmacol.* 2007 Jul 2;566(1-3):94-102.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA